First Time Loading...

Anika Therapeutics Inc
NASDAQ:ANIK

Watchlist Manager
Anika Therapeutics Inc Logo
Anika Therapeutics Inc
NASDAQ:ANIK
Watchlist
Price: 27.59 USD Market Closed
Updated: May 5, 2024
Section:
 

Wall Street
Price Targets

ANIK Price Targets Summary
Anika Therapeutics Inc

Wall Street analysts forecast ANIK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ANIK is 30.94 USD with a low forecast of 22.22 USD and a high forecast of 38.85 USD.

ANIK Lowest Forecast
Wall Street Target
22.22 USD
19% Downside
ANIK Average Forecast
Wall Street Target
30.94 USD
12% Upside
ANIK Highest Forecast
Wall Street Target
38.85 USD
41% Upside
Lowest
Price Target
22.22 USD
19% Downside
Average
Price Target
30.94 USD
12% Upside
Highest
Price Target
38.85 USD
41% Upside
Anika Therapeutics Inc Competitors:
Price Targets
L
2157
Lepu Biopharma Co Ltd
41% Downside
9926
Akeso Inc
26% Upside
VCEL
Vericel Corp
15% Upside
ALNY
Alnylam Pharmaceuticals Inc
49% Upside
L
2157
Lepu Biopharma Co Ltd
41% Downside
9926
Akeso Inc
26% Upside
VCEL
Vericel Corp
15% Upside
ALNY
Alnylam Pharmaceuticals Inc
49% Upside
YMAB
Y-mAbs Therapeutics Inc
27% Upside
I
086890
Isu Abxis Co Ltd
112% Upside
CPRX
Catalyst Pharmaceuticals Inc
85% Upside
DYAI
Dyadic International Inc
435% Upside

Revenue
Forecast

Revenue Estimate
Anika Therapeutics Inc

For the last 8 years the compound annual growth rate for Anika Therapeutics Inc's revenue is 8%. The projected CAGR for the next 3 years is 6%.

8%
Past Growth
6%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Anika Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Anika Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
7%
Average Beat
What are analyst estimates?

See Also

Summary
ANIK intrinsic value, competitors valuation, and company profile.
DCF Valuation
ANIK stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ANIK stock valuation using valuation multiples.
Wall Street Estimates
ANIK price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ANIK stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ANIK's stock price target?
Price Target
30.94 USD

According to Wall Street analysts, the average 1-year price target for ANIK is 30.94 USD with a low forecast of 22.22 USD and a high forecast of 38.85 USD.

What is Anika Therapeutics Inc's Revenue forecast?
Projected CAGR
6%

For the last 8 years the compound annual growth rate for Anika Therapeutics Inc's revenue is 8%. The projected CAGR for the next 3 years is 6%.

ALPHA SPREAD
Join more than 134,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.